@BioStocks

Investor/trader focused primarily in the biopharma sector. Tweets are not investment advice and are not recommendations of any kind.

 Toronto
Joined February 2010
  • Tweets61.8K
  • Following93
  • Followers72.4K
$EYPT
Bio Stocks™
@BioStocksOct 19
$EYPT Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU in Wet AMD – LUCIA did not achieve the primary endpoint
5
1
1
14
5,633
$IRON
2
2
12
4,430
$VSTM
2
2,087
$AVBP
Bio Stocks™
@BioStocksOct 6
$AVBP Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC Did Not Meet Primary Endpoint
4
1
14
6,561
Largest reported hedge-fund stakes in $LQDA (Q2'26 13Fs)
2
3
1
11
8,519
$FHTX and $LLY will not advance further FHD-909. The collaboration will also not advance the Selective SMARCA2 degrader program, and the companies do not anticipate further collaboration activities.
1
7
5,166
$LQDA
1
4
15,041
$QURE
Bio Stocks™
@BioStocksSep 29
$QURE uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression uniqure.gcs-web.com/node/130…
2
1
14
10,701
$KOD
Bio Stocks™
@BioStocksSep 28
$KOD Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD Zenkuda met the primary endpoint (p-value of 0.0007), demonstrating meaningful vision gains as well as rapid and sustained retinal drying with the majority of patients (54%) on 6-month dosing ir.kodiak.com/news-releases/…

Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda...

Zenkuda (tarcocimab tedromer) met the primary endpoint (p-value of 0.0007) demonstrating meaningful vision gains as well as rapid and sustained retinal drying with the majority of patients (54%) on...

ir.kodiak.com
1
6
1
24
9,034
$NVO $LLY
2
1
13
4,263
Load more